article thumbnail

Report: Nurse Understaffing Is Becoming More Deadly for Patients

MedCity News

The percentage of respondents who know of a patient death being caused by nurses being assigned too many patients nearly doubled in the past seven years — from 22% in 2016 to 42% in 2023.

Patients 114
article thumbnail

Staying abreast of regulations with NGS?based viral safety for faster, safer and more ethical lot release of our vaccines

European Pharmaceutical Review

How does that impact the safety of the biologics? Safety is key to the development of any medicine, but the safety considerations linked to bioproduction are more complex because biologics are more sophisticated medicines than small molecules. How are regulatory guidelines adapting to this trend? References.

Ethics 85
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novel oral chemotherapeutic holds potential for stomach cancer patients

European Pharmaceutical Review

The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. New hope for stomach cancer patients.

article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Over the past few years, we have researched the types of evidence used in regulatory decisions for drug product withdrawals due to safety concerns in Europe. Our research showed that in Europe between 1999 and 2016, 35 products were withdrawn. But over time, trends in what evidence is most available and therefore most used, change.

Safety 113
article thumbnail

Will Novartis provide new oral option for chronic hives?

European Pharmaceutical Review

The Bruton’s tyrosine kinase (BTK) inhibitor was evaluated in patients with symptoms inadequately controlled by H1-antihistamines. Approximately 60 percent of patients are inadequately controlled with antihistamines alone. H1-antihistamines are the current first-line treatment in CSU.

Safety 71
article thumbnail

Bayer unit BrainVectis cleared to start Huntington gene therapy trial

pharmaphorum

France’s BrainVectis, a subsidiary of Bayer’s Asklepios BioPharma (AskBio) unit, has been given the green light by regulators in France to start dosing patients with its gene therapy candidate for devastating neurodegenerative disorder Huntington’s disease.

Safety 104
article thumbnail

mRNA non-vaccine therapeutics to generate $2 billion by 2028

European Pharmaceutical Review

The report noted that regulations affecting mRNA therapies are focusing on achieving better patient access and increased reviews of drugs that improve treatment, diagnosis, or prevention of serious conditions. Robust analytical methods are needed to establish safety, potency, and purity of mRNA therapeutics in large-scale manufacturing.